GSK Lifts Guidance After Turnover Beats Expectations — Update

May 1, 2024 · By Helena Smolak . GSK lifted its full-year guidance after first-quarter turnover rose and beat expectations, helped by higher sales in its vaccines and specialty medicines segment.

CouponFollow Extension

13%
OFF

GSK Lifts Guidance After HIV, Cancer Treatments Boost Sales - MSN

1 week from now

GSK’s HIV sales grew 13% to £1.76 billion, boosted by strong demand for Dovato and Juluca treatments as well as long-acting medicines such as Cabenuva and Apretude. In oncology, …

msn.com

3%
OFF

GSK Stays Strong As Healthy Sales Beat Expectations - Yahoo Finance

1 week from now

Apr 26, 2023 · Even after stripping out one-off contributions, underlying revenue and earnings beat expectations by a respectable 3% and 4% respectively, Citi analyst Andrew Baum wrote …

yahoo.com

7%
OFF

GSK Raises Profit Guidance As Vaccine Demand Grows - Yahoo …

1 week from now

May 1, 2024 · It also told shareholders that turnover is expected grow at the upper end of its 5-7% range. GSK said total sales grew by 10%, or 13% excluding Covid-19 related treatments, for …

yahoo.com

12%
OFF

Trending: GSK's 3Q Profits Drive Full-Year Guidance Hike, Despite ...

1 week from now

Oct 6, 2022 · For the year, GSK expects turnover to increase between 12% and 13%, compared with previous guidance of 8% to 10%, and adjusted operating profit to increase between 13% …

morningstar.com

5%
OFF

Britain's GSK Lifts Outlook After Drug Sales Help It Beat Forecasts

1 week from now

Oct 27, 2021 · Britain's GSK lifts outlook after drug sales help it beat forecasts. ... Turnover at the world's biggest vaccine maker by sales rose 5% to 9.1 billion pounds ($12.5 billion) for the …

reuters.com

FAQs about GSK Lifts Guidance After Turnover Beats Expectations — Update Coupon?

Why did GSK lift its full-year guidance?

GSK lifted its full-year guidance after first-quarter turnover rose and beating expectations, helped by higher sales in its vaccines and specialty medicines segment. The British pharmaceutical giant said Wednesday that it now expects turnover growth this year toward the higher end of its previously guided 5% to 7% range. ...

How did GSK perform in 2023?

LONDON (Reuters) -GSK began 2023 with a quarterly performance that beat analyst expectations and extended a series of positive results thanks to strong sales of its vaccines as well as HIV and respiratory medicines. ...

Why did GSK lift its profit forecasts?

GSK has lifted its profit forecasts for the year as it highlighted strong demand for respiratory virus and shingle vaccines. Shares in the company made gains on Wednesday morning as a result. ...

What is GSK doing now?

“We have strengthened capabilities in key technology platforms and completed investments to develop new mRNA vaccines, ultra-long-acting HIV medicines and a promising new medicine for severe asthma. All this supports our future growth and confidence to bring meaningful innovation to patients,” chief executive officer of GSK, Emma Walmsley, said. ...

What's behind GSK's improved outlook?

GSK's improved outlook rests on expected pharmaceuticals sales growth, despite a forecast for lower vaccine sales as a surge in the coronavirus Delta variant delayed an expected recovery, including for its key shingles shot. ...

Does GSK make a strong start to 2024?

GSK makes a strong start to 2024 with... Vaccines sales +16%, +22% ex COVID. Shingrix £0.9 billion +18%, Arexvy £0.2 billion General Medicines sales +1%. Trelegy £0.6 billion +33% Core operating profit +27% (with further positive impact of +8% ex COVID) and Core EPS +28% (with further positive impact of +9% ex COVID). ...